CClinicalTrials.gg
CompletedNCT02811614MISICHUpdated Feb 22, 2023

Minimally-invasive Surgery Versus Craniotomy in Patients With Supratentorial Hypertensive Intracerebral Hemorrhage

An interventional study of Endoscopic Evacuation and Stereotactic Aspiration in Intracranial Hemorrhage, Hypertensive, sponsored by Chinese PLA General Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
733
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The effectiveness of craniotomy in the treatment of intracerebral hemorrhage remains controversial. Two main types of minimally invasive surgery, endoscopic evacuation and stereotactic aspiration, have been attempted for hematoma removal and show some advantages. However, prospective and controlled studies are still lacking. This is a multi-center randomized controlled trial designed to determine whether minimally invasive hematoma evacuation with endoscopic or stereotactic aspiration will improve the outcome in patients with hypertensive intracerebral hemorrhage compared with small-boneflap craniotomy. Patients will be randomly assigned to endoscopy group, stereotactic aspiration group or small-boneflap craniotomy group in a 1:1:1 ratio.

Read the detailed description

Hypertensive intracerebral hemorrhage (HICH) is the most common hemorrhagic stroke. The morbidity and mortality exceed 60% and only 12% patients could live independently. The choice of surgical or conservative treatment for patients with HICH is controversial.

Some minimally invasive neurosurgeries have been applied to hematoma evacuation and may improve prognosis to some extent. In endoscopic evacuation, a small burr hole is created and hematoma is removed through suction and irrigation under neuroendoscope. Endoscopic surgical evacuation promise to maximize hematoma evacuation while minimizing damage to normal tissue. Stereotactic aspiration uses image guidance to place a catheter into the main body of the hematoma and aspirate blood. It is estimated that 720 patients (240 patients in each treatment group) would provide 90% power and a type I error probability of .05 to detect an effect size of 13% with a 10% dropout rate taken into consideration. Patients will receive endoscopic evacuation, stereotactic aspiration or craniotomy according to the results of randomization. Patients will be followed up at 7 days, 30 days and 6 months.

Outcomes of different groups of patients will be collected and compared. The study is designed to find a best surgical method for hypertensive intracerebral hemorrhage.

02

Conditions studied

  • Intracranial Hemorrhage, Hypertensive

Keywords

  • intracerebral hemorrhage,hypertensive
  • minimally invasive surgery
  • neuroendoscopic surgery
  • stereotactic aspiration
03

In context

Cerebral Hemorrhage

476 studies on the registry are indexed under Cerebral Hemorrhage; 181 are open to participants now.

This study's enrollment of 733 is above the median of 100 across 287 interventional studies indexed under Cerebral Hemorrhage.

Browse Cerebral Hemorrhage studies →

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Supratentorial hypertensive intracerebral hemorrhage on CT scan with the hematoma volume ≥25mL
  • Adult patients with GCS score ≥5
  • Admitted within 24h of ictus

Exclusion criteria

Exclusion Criteria:

  • Intracerebral hemorrhage caused by tumor, coagulopathy, aneurysm, or arteriovenous malformation
  • Concurrent head injury or history of head injury
  • Multiple intracerebral hemorrhage
  • Known advanced demential or disability before
  • With indications of terminal brain hernia
  • Severe concomitant diseases that affect life expectancy
  • Patients having taken anti-platelet or anticoagulant drugs for a long time
  • With severe intraventricular hemorrhage
  • Pregnant women
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
733 participants (actual)

Study arms

  • Experimental
    Experimental 1: Endoscopic Evacuation

    Endoscopic hematoma evacuation with the help of a self-developed working channel.

    Procedure: Endoscopic Evacuation

  • Experimental
    Experimental 2: Stereotactic Aspiration

    Place a catheter into the main body of the hematoma and aspirate blood.

    Procedure: Stereotactic Aspiration

  • Active comparator
    Active Comparator: Craniotomy

    Craniotomy with a big bone flap to for hematoma evacuation.

    Procedure: Craniotomy

Interventions

  • ProcedureEndoscopic Evacuation

    Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.

    Also known as: neuroendoscopic surgery

  • ProcedureStereotactic Aspiration

    Using image guidance to aspirate hematoma.

    Also known as: Hematoma Stereotactic Aspiration

  • ProcedureCraniotomy

    Craniotomy with a big bone flap to evacuate intracerebral hematoma.

    Also known as: Craniotomy evacuation of hematoma

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale

    The degree of disability or dependence in the daily activities. The scale runs from 0-6, running from perfect health without symptoms to death.

    Time frame: 6 months

Secondary outcomes

  1. Hematoma Clearance Rate

    A ratio assessing extent of hematoma evacuation, ranging from 0 to 100%.

    Time frame: 24 hours and 3 days

  2. Operation Time

    The time from skin incision to the end of surgery.

    Time frame: 24 hours

  3. Intraoperative Blood Loss

    Volume of blood lost during operation.

    Time frame: 24 hours

  4. Postoperative Glasgow Coma Scale

    A neurological scale to record the conscious state of patients at 1 week after surgery.

    Time frame: 7 days

  5. Rebleeding Rate

    The percentage of patients that suffer from rebleeding after surgery. Rebleeding usually occurs within 3 days after surgery.

    Time frame: 3 days

  6. Days of ICU Stay

    The time an ICH patient has to stay in intensive care unit after surgery.

    Time frame: 14 days

  7. Mortality

    The percentage of patients that die within a month after the onset of hypertensive intracerebral hemorrhage.

    Time frame: 30 days

  8. Intracranial Infection Rate

    Percentage of patients that get intracranial infection. The infection should be confirmed by cerebrospinal fluid tests.

    Time frame: 7 days

  9. Barthel Index

    An ordinal scale used to measure performance of patients in activities of daily living. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.

    Time frame: 6 months

  10. Hospitalization expenses

    Total expenses during neurosurgery hospitalization

    Time frame: 6 months

07

Study locations

1 site
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
08

References and documents

Publications

  • Xu X, Zheng Y, Chen X, Li F, Zhang H, Ge X. Comparison of endoscopic evacuation, stereotactic aspiration and craniotomy for the treatment of supratentorial hypertensive intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials. 2017 Jun 28;18(1):296. doi: 10.1186/s13063-017-2041-1. PubMed 28659171 ↗

Individual participant data

Plan to share: Yes

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02811614
Lead sponsor
Chinese PLA General Hospital
Collaborators
Jingzhou Central Hospital, Wuhan No.1 Hospital, Yichang Central People's Hospital, Second Hospital of Jilin University, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, Tang-Du Hospital, First Affiliated Hospital, Sun Yat-Sen University, Jiangmen Central Hospital, Jilin Province People's Hospital, Siping Central People's Hospital, Minzu Hospital of Guangxi Zhuang Autonomous Region, Taihe Hospital
Responsible party
Xiaolei Chen (Professor, Chinese PLA General Hospital) — Principal investigator
First posted
Jun 23, 2016
Start date
Jul 1, 2016
Primary completion
Jun 30, 2022
Completion
Jul 31, 2022
Last update
Feb 22, 2023

Study contacts

Xiaolei Chen, MD
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion